|1.||Díaz-Rubio, Eduardo: 9 articles (01/2012 - 06/2004)|
|2.||Yoshida, Yoichiro: 8 articles (06/2015 - 05/2011)|
|3.||Hoshino, Seiichiro: 8 articles (06/2015 - 05/2011)|
|4.||Yamashita, Yuichi: 8 articles (06/2015 - 05/2011)|
|5.||Rivera, Fernando: 8 articles (01/2013 - 09/2007)|
|6.||Van Cutsem, Eric: 6 articles (11/2015 - 06/2004)|
|7.||Schmoll, Hans-Joachim: 6 articles (11/2015 - 08/2003)|
|8.||Tabernero, Josep: 6 articles (11/2015 - 06/2004)|
|9.||Aisu, Naoya: 6 articles (06/2015 - 01/2013)|
|10.||Haller, Daniel G: 5 articles (11/2015 - 01/2007)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
03/01/2009 - "XELOX-RT was feasible and showed promising efficacy when treating patients with primary inextirpable colorectal cancer, establishing high local control rate."
05/01/2007 - "Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX?"
04/01/2007 - "The aim of the present study was to define the feasibility and efficacy of XELOX administered through a new chronomodulated schedule in untreated advanced colorectal cancer (CRC) patients. "
11/01/2006 - "An international phase III trial (NO16966) was initiated to demonstrate the noninferiority of XELOX to FOLFOX4 for the first-line treatment of metastatic colorectal cancer. "
09/01/2012 - "Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach."
|2.||Stomach Neoplasms (Stomach Cancer)
03/01/2010 - "The XELOX regimen shows good efficacy with an acceptable toxicity profile in advanced or recurrent gastric cancer patient."
01/01/2012 - "For patients with a preoperative diagnosis of unresectable gastric cancer, the efficacy of the FLEEOX regimen, which combines arterial with venous administration, was better than that of the XELOX regimen, using venous administration only. "
01/01/2010 - "Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer."
08/01/2010 - "XELOX regimen can be effectively and safely applied as first-line treatment for advanced gastric cancer patients."
06/01/2015 - "In this study, we collected 32 PBMC samples from 16 XELOX-treated patients with gastric cancer and analyzed the patterns of immune cells. "
|3.||Rectal Neoplasms (Rectal Cancer)
11/28/2011 - "Neoadjuvant chemoradiotherapy using the XELOX regimen in rectal cancer patients obviously reduced the TNM staging and improved the pathological complete response rate. "
11/01/2013 - "Preoperative chemoradiotherapy followed by XELOX might be effective for the treatment of locally advanced lower rectal cancer. "
11/28/2011 - "This study evaluated the efficacy and safety of neoadjuvant chemoradiotherapy with the XELOX regimen in rectal cancer patients. "
11/01/2014 - "A 69- year-old man with metastatic rectal cancer received 4 courses XELOX therapy. "
04/01/2012 - "[A case of locally advanced rectal cancer had a pathological complete response to XELOX Therapy]."
|4.||Colonic Neoplasms (Colon Cancer)
06/01/2013 - "[A case of metastatic colon cancer effectively treated by XELOX and IRIS]."
11/10/2015 - "XELOX improved OS compared with bolus FU/FA in patients with resected stage III colon cancer after a median follow-up of almost 7 years. "
10/01/2013 - "Conversion P-XELOX therapy yields high response and resectability rates for patients with metastatic colon cancer with extensive liver involvement."
08/01/2013 - "XELOX and FOLFOX4 have both been recommended as adjuvant therapy for stage III colon cancer. "
08/01/2013 - "Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer."
|5.||Neoplasm Metastasis (Metastasis)
01/01/2008 - "50 patients with resectable liver metastases received neoadjuvant XELOX or FOLFOX4 for six cycles (3 months). "
09/01/2013 - "Seven patients (50%) received SOX, and the others received XELOX as first-line therapy for initially unresectable metastases from colorectal cancer. "
06/07/2013 - "Patients in the XELOX and FOLFOX6 groups were younger at the time of treatment (median age 55.2 years; 51.2 years vs 58.9 years), had more undifferentiated tumors (70.1%; 70.8% vs 61.4%), and more lymph node metastases (80.8%; 83.3% vs 57.7%), respectively. "
11/01/2011 - "[Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node]."
01/01/2008 - "Our data suggests that XELOX regimen seems to be useful in unresectable liver only metastases from colorectal cancer because of its activity, feasibility and tolerability. "
|5.||Leucovorin (Folinic Acid)
|8.||erlotinib (CP 358,774)
|1.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)